Two patients with suspected cancer presenting to rural and peri-urban clinics in Botswana

Neo Tapela, MD
Scott Dryden-Peterson, MD
Continuing Medical Education Announcement

Harvard Medical School
RSS 3081: Monthly BOTSOGO Tumor Board; 2017-2018 Academic Year

Today’s Objectives:
• Describe the need for timely cancer case presentation and referral to treatment
• Formulate a multi-disciplinary plan for the care of common and complex oncologic cases
• Adopt successful, sustainable strategies to mitigate barriers to quality cancer care common in resource constrained environments

Target Audience:
Oncologists, internists, surgeons, radiation oncologists, infectious disease specialists, nurses, physicists, therapists, technicians, research staff, administrators, policy makers.
Financial Relationships

The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of the activity) consumed by, or used on, patients:

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Type of Financial Relationship</th>
</tr>
</thead>
</table>

All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have reported no financial relationships related to the content of this activity.
Accreditation Statement
The Harvard Medical School is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement
The Harvard Medical School designates this live activity for a maximum of 1 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the criteria of the Massachusetts Board of Registration in Medicine for 1.0 credits of Risk Management Study.

Disclosure Statement
In accord with the disclosure policy of the Medical School as well as standards set forth by the Accreditation Council for Continuing Medical Education, course planners, speakers, and content reviewers have been asked to disclose any relevant relationship they, or their spouse or partner, have to companies producing, marketing, re-selling or distributing health care goods or services consumed by, or used on, patients.
Claim your CME credits!

• To claim your CME credit for attendance at this session of the BOTSOGO Tumor Board, please fill out our survey after the Tumor Board.

• You can do this at your convenience on your personal or work computer by navigating to www.botsogo.org
  • Click “What We Do”
  • Click “Tumor Board”
  • Click the link under the section “Continuing Education Credits,” and complete and submit the survey

• Or follow the link that was emailed to our MGH BOTSOGO email list: www.tinyurl.com/tumourboard
Background: Global

- Over 72% deaths due to cancer are in LMICs;
- For a given cancer, survival is poor in LMICs;
- Delayed diagnosis and treatment are a major contributor poor survival;
- Only 20%-50% breast cancer patients in LMICs are diagnosed in earlier stages, compared with 70% in HICs. (Unger-Saldaña, World J Clin Oncol 2014)
Background: Botswana

- BNCR: 50% cervical and 77% breast cancers are diagnosed in stage III or IV

- Brown et al 2016:
  - Median time from symptom onset to initial clinic visit = 1 mo
  - Median time from symptom onset to oncology care = 13.3 mo
  - HIV made no difference
Title: Hurrying up to save lives - An innovative multi-component programmatic intervention for timely cancer diagnosis in Botswana

Aim: To implement and evaluate a multicomponent intervention intended to diagnose cancers early

Training
Referral algorithm
Coordination: weekly support calls, scheduling, path follow up

Coordination: calls after every visit, SMS reminders, transport support

1st visit (suspected cancer)

Diagnosis (cancer vs not)*
*or death, LTFU
Potlako Intervention:

1. Primary provider education/support
   - Single-day session focused on recognizing early cancer symptoms and diagnostic approach
   - Nurses/doctors from all clinics/health posts/hospital in April 2016 and Feb 2017
   - Substantial improvement in cancer knowledge and self-reported confidence in managing patients
   - Weekly support calls or visits from Potlako team
Potlako Intervention:

2. Navigational support to patients and clinicians
   - Patients enrolled in tracking system
   - Called after each appointment and booking assistance for investigations, SMS reminders
   - Follow up pathology results
   - Communication to oncologists/surgeons/other specialists for challenging cases

3. Financial support for transport to visits
Progress so far

2 trainings held (259 trained, 100% facilities in KE)

501 patients enrolled and assisted
- 74% female, 28% HIV+ (14% missing values)
- 77% ECOG 0 or 1 (10% missing)
- 76% pain score 0-2 out of 5 (7% missing)
- 16% (82) died, median f/u 6 months
- 121 cancers (97 confirmed, 24 probable)

5 abstracts, 1 manuscript

CANCER TYPES (N=121)

- Cervical 31%
- Breast 26%
- Esophageal 15%
- Prostate 6%
- Penile 6%
- KS 5%
- Other 11%
- Other 11%
71yoM HIV- with 2cm breast lump:

71yo farmer
- No formal schooling
- Previously worked in underground gold mine for many years
- No tobacco or alcohol use
- No family history of cancer
- Married, has 7 children
- Lives in an electrified home with 11 family members
- Makes 1000-2500 BWP/mo
- Utilizes traditional healers routinely
71yo M HIV- with 2cm breast lump:

Painless lump
- First noticed in Dec 2016, eval in non-Kweneng East clinic
- Seen at Molepololoe primary clinic in May 2017, by Potlako trained FNP
- Referred to SLH within 1wk for U/S; Potlako facilitated booking of scan/CXR

U/S findings: Complex cystic mass noted
- FNA done next day
- Patient received results 2wks later, but did not understand them or whether it was important
- Potlako facilitated booking of MDT visit
71yoM HIV- with 2cm breast lump:

Evaluated at breast PMH MDT, June 2017
- Biopsy done and results available 2wks later
- Confirmed infiltrating ductal carcinoma, stage IIB (T2, N1)
- Treatment plan developed, referred for neoadjuvant

PMH Oncology
- Missed booked appointment, no money for transport
- Potlako re-booked, forwarded transport money
- Seen but needed to repeat labs (now old)
- Started neoadjuvant chemo (?AC) in July
44yoF HIV+ with vaginal bleeding and pain:

- 44yo government employee
  - Single, mother of two
  - Lives in Molepololoe
  - Income 1000-2500 BWP/mo
  - No tobacco or alcohol use
  - No family history of cancer
  - Diagnosed with HIV in 2013, CD4 nadir 142 but no prior AIDS events
  - Started ART (TDF/FTC/EFV) in 2013; current CD4 320, HIV VL <400
44yoF HIV+ with vaginal bleeding and pain:

Symptoms started in 2015
- Post-coital bleeding
- Lower abdominal pain

Early evaluation (per patient report) at a clinic in Molepolole
- Treatment for STI, several times
- ‘Normal’ pap smear

Self-referred to SLH with progressive bleeding, Aug 2016
- Admitted to FSW, enrolled in Potlako at this time
- Abnormal cervix on exam
44yoF HIV+ with vaginal bleeding and pain:

- Biopsy performed by SLH GYN (early Aug)
  - Returned at 2, 3, and 4 weeks to get result (resulted at 10d, but not noted by clinical staff)
  - Confirmed poorly differentiated SCC of cervix
  - Potlako team informed patient and clinician that results were out; arranged for U/S
- Seen in GYN MDT at PMH (mid Sept)
- Staged IIB cervical cancer
- Referred for chemoRT
44yoF HIV+ with vaginal bleeding and pain:

Progressive fatigue and pain
- Guarantee form received mid-Dec
- Referred for chemoradiation

Chemoradiation at GPH
- EBRT: 23 fractions of 2 Gy (total 46 Gy)
- Brachy: 4 fractions of 7 Gy (total 28 Gy)
- Almost complete response
Discussion:

Ideas for addressing *persistent and large challenges*:

- Majority of cancer suspects are only enrolled in Potlako at SLH or after substantial delay
- Substantial number of cancer suspects/cases refuse work-up and treatment
- Clinic cancellations at all levels (diagnostic procedures, specialist visits, MDTs, oncology) substantially delay eval
- Limited access to specialized areas: urology, ENT, thoracic, hepatobiliary
- Difficult to predict who will need transport support until visit already missed and delay happened
- Outages of reagents and equipment: PSA, mammography, scopes, clips
Summary:

- Patients face significant challenges navigating the health system for cancer-related evaluation and care (socioeconomic, health system limitations)
- Potlako, and other developments (e.g. pathology turn around, MDTs) have made some improvements
- Challenges and questions remain: e.g. prostate cancer diagnostic work up, GI and Head and Neck cancers
- Potlako enrollment planned for 1 more year. Interim analysis to be shared by Dec 2017
Additional Summary/Conclusions from Tumor Board discussion

Case #1 (breast):
- Diagnostic evaluation a ‘success’ and clear impact of Potlako intervention
- Concern expressed about comprehensiveness of staging (patient determined to be metastatic but basis not known) and possibility of non-cancerous reasons for abnormalities seen
- Tamoxifen would be key part of treatment for metastatic, in setting of unknown/delayed knowledge ER status, advised use as vast majority of male breast cancers ER+
- Local control with radiation, hormone, surgery will be important even in met disease

Case #2 (cervical):
- Knowledge of accessing results in IPMS limited, need to use name/Omang rather than PA/PM numbers to have best success
- Clinicians need to be informed that TOT is ~2wks, and improved
- Bulk of delay in guarantee/booking RT process

Additional notes:
More in-depth discussion of Potlako program (successes and challenges faced) will be of interest to our Tumor Board community, including discussion of additional cases with different diagnoses.